Recent 52-Week Lows
8.97k followers • 3 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that have set 52-week lows within the last week. This list is generated daily, ranked by market cap and limited to the top 30 stocks that meet the criteria.
Curated by Yahoo Finance
Follow this list to discover and track stocks that have set 52-week lows within the last week. This list is generated daily, ranked by market cap and limited to the top 30 stocks that meet the criteria.
Background
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.
How are these weighted?The stocks in this watchlist are weighted equally.
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| Recent 52-Week Lows | - | - | - | - |
| ^GSPC | +0.52% | +6.69% | +14.94% | +3613.43% |
3 symbols
- Bloomberg
Gilead’s Remdesivir Becomes First Virus Treatment to Win FDA Nod
(Bloomberg) -- The U.S. Food and Drug Administration approved Gilead Sciences Inc.’s antiviral therapy remdesivir on Thursday, making it the first drug to obtain formal clearance for treating the coronavirus.Regulators had granted an emergency-use authorization for remdesivir earlier this year, and since then the drug has become a widely used therapy in hospitalized Covid-19 patients. It was given to President Donald Trump this month when he was diagnosed with the virus.The approval of remdesivir, sold under the brand name Veklury, will allow Gilead to market the drug and talk about its benefits to doctors, nurses, and patients. That could help solidify its position as a go-to medicine for Covid-19 patients even as other drugs for the disease begin to reach the market.“Veklury is now the first and only approved Covid-19 treatment in the United States,” Gilead said in a statement. While the drug was in short supply initially, Gilead said that the medicine is now widely available in hospitals across the country as manufacturing capacity has rapidly expanded.The drug hasn’t been proven to reduce deaths from Covid-19. In a World Health Organization trial, the medicine failed to reduce fatalities, according to preliminary results that were posted on preprint servers last week.Gilead has criticized the WHO study. In a letter posted on the company’s website, Chief Medical Officer Merdad Parsey said the findings don’t negate other results.Shares of Gilead gained 6.3% in pre-market trading on Friday. Analysts estimate that remdesivir will have sales of $2.17 billion this year, according to 13 surveyed by Bloomberg.The company said in June that it will charge U.S. hospitals roughly $3,120 for most patients who need remdesivir.Read more: Gilead Chooses Middle Ground in Pricing of Coronavirus DrugThe approval is based on a U.S. government-sponsored trial involving more than 1,000 hospitalized coronavirus patients that found that those who received the drug recovered about five days faster than those who got a placebo.The overall side-effect rate was similar to the placebo in the government study. The most common side effects are nausea and elevated liver enzymes, according to the product’s label.Read more: Where Are We in the Quest for Coronavirus Treatments?: QuickTake(Updates with pre-market trading in seventh paragraph. An earlier version of this article misspelled the drug name in the headline.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- Motley Fool
Gilead's Remdesivir First Drug to Win FDA Approval for Coronavirus
On Thursday, the U.S. Food and Drug Administration (FDA) granted approval to Gilead Sciences' (NASDAQ: GILD) remdesivir -- sold under the brand name Veklury -- to treat the illness in patients 12 years of age and older in cases requiring hospitalization. Gilead is currently developing an inhaled version. The FDA's approval was based on data from three clinical studies of the drug.
- Zacks
Stimulus or No? Plus News from GILD, Earnings from INTC & MAT
Gilead (GILD) shares are up 4% in late trading on an announcement that the FDA has granted full approval to its remdesivir treatment.
